Indication
HIV-Associated Lipodystrophy Syndrome
1 clinical trial
2 products
Clinical trial
Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIVStatus: Completed, Estimated PCD: 2022-06-17
Product
DolutegravirProduct
Antiretroviral